9FBX | pdb_00009fbx

C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 5-(1-benzyl-4-chloro-1H-imidazol-2-yl)-1,3-dimethylpyridin-2(1H)-one


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.60 Å
  • R-Value Free: 
    0.175 (Depositor), 0.181 (DCC) 
  • R-Value Work: 
    0.150 (Depositor), 0.163 (DCC) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 9FBX

Ligand Structure Quality Assessment 


This is version 1.1 of the entry. See complete history

Literature

Structure- and Property-Based Optimization of Efficient Pan-Bromodomain and Extra Terminal Inhibitors to Identify Oral and Intravenous Candidate I-BET787.

Hirst, D.J.Bamborough, P.Al-Mahdi, N.Angell, D.C.Barnett, H.A.Baxter, A.Bit, R.A.Brown, J.A.Chung, C.W.Craggs, P.D.Davis, R.P.Demont, E.H.Ferrie, A.Gordon, L.J.Harada, I.Ho, T.C.T.Holyer, I.D.Hooper-Greenhill, E.Jones, K.L.Lindon, M.J.Lovatt, C.Lugo, D.Maller, C.McGonagle, G.Messenger, C.Mitchell, D.J.Pascoe, D.D.Patel, V.K.Patten, C.Poole, D.L.Shah, R.R.Rioja, I.Stafford, K.A.J.Tape, D.Taylor, S.Theodoulou, N.H.Tomlinson, L.Wall, I.D.Wellaway, C.R.White, G.Prinjha, R.K.Humphreys, P.G.

(2024) J Med Chem 67: 10464-10489

  • DOI: https://doi.org/10.1021/acs.jmedchem.4c00959
  • Primary Citation Related Structures: 
    9FBX, 9FBY

  • PubMed Abstract: 

    The bromodomain and extra terminal (BET) family of bromodomain-containing proteins are important epigenetic regulators that elicit their effect through binding histone tail N -acetyl lysine (KAc) post-translational modifications. Recognition of such markers has been implicated in a range of oncology and immune diseases and, as such, small-molecule inhibition of the BET family bromodomain-KAc protein-protein interaction has received significant interest as a therapeutic strategy, with several potential medicines under clinical evaluation. This work describes the structure- and property-based optimization of a ligand and lipophilic efficient pan-BET bromodomain inhibitor series to deliver candidate I-BET787 ( 70 ) that demonstrates efficacy in a mouse model of inflammation and suitable properties for both oral and intravenous (IV) administration. This focused two-phase explore-exploit medicinal chemistry effort delivered the candidate molecule in 3 months with less than 100 final compounds synthesized.


  • Organizational Affiliation
    • GSK Medicines Research Centre, Stevenage, Hertfordshire SG1 2NY, U.K.

Macromolecule Content 

  • Total Structure Weight: 14.22 kDa 
  • Atom Count: 1,203 
  • Modeled Residue Count: 113 
  • Deposited Residue Count: 115 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Bromodomain-containing protein 2115Homo sapiensMutation(s): 0 
Gene Names: BRD2KIAA9001RING3
UniProt & NIH Common Fund Data Resources
Find proteins for P25440 (Homo sapiens)
Explore P25440 
Go to UniProtKB:  P25440
PHAROS:  P25440
GTEx:  ENSG00000204256 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP25440
Sequence Annotations
Expand
Reference Sequence

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.60 Å
  • R-Value Free:  0.175 (Depositor), 0.181 (DCC) 
  • R-Value Work:  0.150 (Depositor), 0.163 (DCC) 
Space Group: P 21 21 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 71.755α = 90
b = 52.427β = 90
c = 31.92γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
XDSdata reduction
Aimlessdata scaling

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

& Funding Information

Deposition Data

  • Released Date: 2024-06-26 
  • Deposition Author(s): Chung, C.

Funding OrganizationLocationGrant Number
Not funded--

Revision History  (Full details and data files)

  • Version 1.0: 2024-06-26
    Type: Initial release
  • Version 1.1: 2024-07-10
    Changes: Database references